Develops and commercializes AI-driven precision cardiovascular medicine tests to improve heart disease diagnosis and treatment.
Cardio Diagnostics Holdings, Inc., headquartered in Chicago, Illinois, specializes in the development and commercialization of epigenetics-based clinical tests tailored for cardiovascular disease. The company's flagship product, Epi+Gen, is a pioneering three-year symptomatic coronary heart disease (CHD) risk assessment test designed to predict and prevent CHD events, such as heart attacks.
Founded in 2017, Cardio Diagnostics is at the forefront of leveraging cutting-edge biotechnology to advance precision medicine in cardiovascular health. The company's commitment to innovative diagnostic solutions aims to provide healthcare professionals and patients with reliable tools for early detection and personalized management of CHD risks.
With a focus on improving patient outcomes through advanced diagnostic testing, Cardio Diagnostics continues to expand its research and development efforts, reinforcing its position as a leader in epigenetics-based clinical testing for cardiovascular diseases.